MX2018004361A - Nuevos compuestos para el tratamiento de la fibrosis quistica. - Google Patents

Nuevos compuestos para el tratamiento de la fibrosis quistica.

Info

Publication number
MX2018004361A
MX2018004361A MX2018004361A MX2018004361A MX2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A
Authority
MX
Mexico
Prior art keywords
cystic fibrosis
treatment
novel compounds
cftr
stabilizing
Prior art date
Application number
MX2018004361A
Other languages
English (en)
Inventor
V Patel Sachin
A Gfesser Gregory
John Robert Newsome Gregory
Desroy Nicolas
Akkari Rhalid
Emiel Van Der Plas Steven
D Cowart Marlon
R Kym Philip
Wang Xueqing
Jonathan Alvey Luke
Luc Marie Gosmini Romain
Isabelle Roger Claes Pieter
S Brown Brian
Shrestha Anurupa
Marie Bock Xavier
De Lemos Elsa
Duthion Béranger
Gaëtan Housseman Christopher
Karel Jansen Koen
Ji Jianguo
Mammoliti Oscar
Jeanne Marie Menet Christel
Merayo Merayo Nuria
C Swift Elizabeth
Jules Hector De Wilde Gert
Marie Elise Palisse Adeline
Rafaël Pizzonero Mathieu
Tse Chris
E Conrath Katja
Cyr Douglas
Lefrancois Jean-Michel
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2018004361A publication Critical patent/MX2018004361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Abstract

Un agente corrector capaz de estabilizar una proteína reguladora de la conductancia transmembrana en la fibrosis quística (CFTR) recién sintetizada, útil en el tratamiento de la fibrosis quística.
MX2018004361A 2015-10-09 2016-10-07 Nuevos compuestos para el tratamiento de la fibrosis quistica. MX2018004361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239699P 2015-10-09 2015-10-09
PCT/IB2016/056035 WO2017060879A1 (en) 2015-10-09 2016-10-07 Novel compounds for treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
MX2018004361A true MX2018004361A (es) 2018-09-18

Family

ID=57200058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004361A MX2018004361A (es) 2015-10-09 2016-10-07 Nuevos compuestos para el tratamiento de la fibrosis quistica.

Country Status (9)

Country Link
US (1) US10130622B2 (es)
EP (1) EP3359540A1 (es)
JP (1) JP2018529707A (es)
CN (1) CN108602816A (es)
AU (1) AU2016333907A1 (es)
BR (1) BR112018007165A2 (es)
CA (1) CA3000802A1 (es)
MX (1) MX2018004361A (es)
WO (1) WO2017060879A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191010A1 (en) * 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Substituted chromanes and method of use
MX2018004359A (es) * 2015-10-09 2018-05-01 Abbvie Sarl Pirazolo [3,4-b] piridin-6-carboxamidas n-sulfoniladas y metodo de uso.
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939558B2 (en) 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PT2489659T (pt) 2004-06-24 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8436014B2 (en) 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
CA2891962A1 (en) * 2012-11-20 2014-05-03 Discoverybiomed, Inc. Small molecule cftr correctors
AU2014264936B2 (en) 2013-05-07 2018-09-27 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2015018823A1 (en) 2013-08-08 2015-02-12 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CN107427490A (zh) 2014-10-31 2017-12-01 艾伯维公司 取代的四氢吡喃和使用方法
CA3191010A1 (en) 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Substituted chromanes and method of use

Also Published As

Publication number Publication date
BR112018007165A2 (pt) 2019-01-22
AU2016333907A1 (en) 2018-04-12
CA3000802A1 (en) 2017-04-13
JP2018529707A (ja) 2018-10-11
US20170100386A1 (en) 2017-04-13
WO2017060879A1 (en) 2017-04-13
EP3359540A1 (en) 2018-08-15
CN108602816A (zh) 2018-09-28
US10130622B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
IL277491A (en) Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
MX2018004361A (es) Nuevos compuestos para el tratamiento de la fibrosis quistica.
ZA201902124B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2015328174A8 (en) Modulators of cystic fibrosis transmembrane conductance regulator
EP3458108A4 (en) POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
MX2020005753A (es) Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
MX2021013638A (es) Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quistica.
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2019010155A (es) Arnm de cftr optimizado por codón novedoso.
EP3099784A4 (en) Improved carbon dioxide fixation via bypassing feedback regulation
MX2018003678A (es) Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion.
EP3368580A4 (en) ALTERNATIVE POST-TREATMENT OF STABILIZATION OF HIGHLY DISORDERED CELLULOSES
EP3254704A4 (en) Hydrogen peroxide solution supply apparatus
EP3615084A4 (en) MEMBRANE-ACTIVE MOLECULES
EP3634489A4 (en) IMPROVED METHODS FOR GENERATING SMALL MOLECULAR DEGRADERS AND DIMERIZERS
MY174200A (en) Process for reducing the chlorine content of organotetraphosphites
EP3448369A4 (en) COMPOUNDS AND COMPOSITIONS FOR TREATING THE METABOLISM SYNDROME AND METHOD THEREFOR
EP3279660A4 (en) Preservative solution for heme protein, and method for stabilizing heme protein
EP3646849A4 (en) SINGULET OXYGEN TRAP
EP3435995A4 (en) METHOD FOR THE TREATMENT OF METABOLISM TROUBLES
MX2017010899A (es) Proceso para la preparacion de triazoles.
AU2016903020A0 (en) Treatment for fibrosis
AU2015905412A0 (en) Quality Integral regulator Software Development Project (VENQIR)
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid